Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Starling Oncology, Inc.TOI · Entity 5327 | Chief Accounting Officer | November 15, 2022 | November 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Starling Oncology, Inc.
Report date November 15, 2022 · Filed November 23, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,318 |
Reported balance
After 2022-11-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-11-15 · Sale · Disposed 190 · Balance 29,318 F1: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.
F2: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2022 Filed Nov 21, 2022 22:36 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 52,722 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001799191-22-000043 · edgardoc.xml · derivative · entry 2 Simoneit Diona · CIK 0001921432 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,722 Underlying: Common Stock · 52,722 shares Expires 2032-11-17 F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:36 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 10,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-22-000043 · edgardoc.xml · nonDerivative · entry 1 Simoneit Diona · CIK 0001921432 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,705 F1 · price: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon Stock | 190 | $2.03 | $385.28 |
DisclosureSEC source: 0001799191-22-000015 · edgardoc.xml · nonDerivative · entry 1 Simoneit Diona · CIK 0001921432 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,318 F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 23, 2022 01:08 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 190 | $2.03 | $385.28 |
DisclosureSEC source: 0001799191-22-000053 · edgardoc.xml · nonDerivative · entry 1 Simoneit Diona · CIK 0001921432 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,318 F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.